Imunon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imunon, Inc. (Nasdaq: IMNN) on August 11, 2026. The report discloses the approval of new compensatory programs for certain executive officers, allowing them to receive a portion of their base salary in the form of common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change is the implementation of a salary deferral program for three executive officers, effective for pay periods beginning in July and August 2026. The specific terms are as follows:
- Stacy Lindborg (President and CEO): May elect up to 50% of base salary in shares. Additional shares issued range from 12% to 35% of the net stock payment depending on the issuance date.
- Michael Tardugno (Executive Chairman): May elect up to 100% of base salary in shares. Additional shares issued range from 20% to 40% of the net stock payment depending on the issuance date.
- Douglas Faller (Chief Medical Officer): May elect up to 40% of base salary in shares. Additional shares issued are 12% to 15% of the net stock payment.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. The shares issued to Dr. Lindborg and Mr. Tardugno are exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Shares for Dr. Faller are issued under the 2018 Stock Incentive Plan.
Investor Verification Checklist
- Verify the total number of shares issued to executives under this program in subsequent filings (e.g., Form 4).
- Confirm the impact of these stock issuances on the company's fully diluted share count.
- Review the 2018 Stock Incentive Plan to understand the remaining pool of shares available for issuance.
- Monitor future 8-K filings for any changes to executive compensation or additional departures/appointments.